According to the research report published by Future Market Insights, the global orthobiologics market is expected grow at a slow rate during the assessment period 2017-2027. However, it did not reflect slack or negative growth since past years and is likely to show a slow yet an upward rise in the coming years.
The revenue generated by global orthobiologics market in 2017 reached US$ 4869 Mn and by the end of the assessment year, it is estimated to reach a value less than US$ 7 Bn. The research study portrays several opportunities in the global orthobiologics market. As mentioned in this study, the rising geriatric population can be considered as a beneficial prospect.
Increasing geriatric population offers surplus opportunities for the manufactures of orthobiologics. The major root of amputations are diseases related to ageing as osteoarthritis, musculoskeletal diseases, spine deformity, etc. Increase incidence of accidents owing to increasing urbanization is also a major factor expected to create numerous opportunities for orthobiologics manufacturers. Elevating surgical procedures also presents growth opportunities for the market.
The increased incidences of trauma cases, lifestyle related diseases and other chronic disorders have led to rise in number of orthopaedic surgeries at a global level. This growing trend is anticipated to increase the sales of orthobiologics products in present and forthcoming years.
Emergence of online sales channel and government initiatives bot are contributing to the growth of the market. Manufacturers are focussed on creating sales directly through their company’s website to target more customers and without the interference of third-party distributors. This enables the manufacturers to eliminate the variation in product pricing owing to the involvement of third-party suppliers.
Bone graft substitutes continue to exert a hold on the global market
Bone graft substitute segment in the product type category is expected to dominate the global market in the years to follow. This segment was a lucrative one since 2012. During the 2012-2016 timeline, bone graft substitute segment reflected high growth opportunities and led the global market.
This trend is observed in the current market scenario and is expected to continue over the period of assessment. In 2017, bone graft substitute segment registered a value of US$ US$ 2521.6 Mn and is according to the growth trend exhibited by this segment, it is estimated to reach a market valuation of above US$ 3 Bn by the end of 2027. During the forecast period of 2017-2027, it is poised to reflect a CAGR of 3.0%.
Xenografts to show high potential for growth adding to the domination of bone graft substitutes
Bone graft substitute segment is further analysed and divided into allograft, xenograft, synthetic and bone morphogenetic protein sub segments. Of these, xenograft sub segment is expected to run at the highest pace to register a meteoric CAGR of 10.0% throughout the period of forecast. This segment is the second largest in terms of market value. Allograft and synthetic sub segments have a large yet almost equal contribution to the revenue of the parent segment.
The allograft sub segment is estimated to reach a valuation of US$ 937.5 Mn leading other sub segments. However, the synthetic sub category is poised to grow at a relatively higher rate than allografts in the coming years.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
The global orthobiologics market is segmented in detail so as to cover every aspect of the market and present a complete market intelligence in front of the reader.
By Product Type
- Bone Growth Stimulators (BGS)
- Non-Invasive Electrical BGS
- Invasive Electrical BGS
- Ultrasound BGS
- Single Injection Viscosupplements
- Three Injection Viscosupplements
- Five Injection Viscosupplements
- Bone Graft Substitute
- Bone Morphogenetic Protein
By End User
- Ambulatory Surgical Centres
- Orthopaedics Clinics
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific excluding Japan (APEJ)
- Middle East and Africa (MEA)